OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Neal on Immunotherapy Combinations in Lung Cancer

October 27th 2016

Joel Neal, MD, PhD, assistant professor of Medicine (Oncology), Stanford University Medical Center, discusses what immunotherapy combinations oncologists are currently using in the treatment of patients with lung cancer.

Dr. Jonathan D. Schoenfeld on Radiation/Immunotherapy Combinations

October 27th 2016

Jonathan D. Schoenfeld, MD, MPhil, MPH, director, melanoma radiation oncology, physician, assistant professor of radiation oncology, Harvard Medical School, Dana-Farber Cancer Institute, discusses the potential benefit of using radiation and immunotherapy in combination.

Dr. Neeraj Agarwal on PROSTVAC and Other Immunotherapies in Prostate Cancer

October 27th 2016

Neeraj Agarwal, MD associate professor in the Division of Oncology, Department of Medicine, director of the Genitourinary Medical Oncology Program, Huntsman Cancer Institute at the University of Utah, discusses the pox viral vaccine rilimogene galvacirepvec/rilimogene glafolivec (PROSTVAC) and the future of immunotherapy in prostate cancer.

Dr. Zamarin on Immunotherapy as a Staple in the Future of Cancer Treatment

October 27th 2016

Dmitriy Zamarin, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the ways in which immunotherapy is slated to play a major role in multiple cancer types.

Dr. Lukas on Immunotherapy in Glioblastoma

October 26th 2016

Rimas V. Lukas, MD, associate professor of Neurology, director, Medical Neuro-Oncology, University of Chicago Medicine, discusses some of the exciting advances recently seen with immunotherapy in the treatment of patients with glioblastoma

Dr. Velcheti on Potential of Alectinib in Frontline ALK-Positive NSCLC

October 26th 2016

Vamsidhar Velcheti, MD, an assistant professor of Medicine at Cleveland Clinic Lerner School of Medicine, discusses the ALK inhibitor alectinib (Alecensa) and what potential the agent could have in the frontline setting for patients with ALK-positive non–small cell lung cancer (NSCLC). Velcheti shared this insight in an interview during the 2016 OncLive State of the Science Summit on Non–Small Cell Lung Cancer.

Dr. Leis on Advances in CLL

October 26th 2016

Jose Leis, MD, associate professor of Medicine, Mayo Clinic, discusses treatment-related advances in the field of chronic lymphocytic leukemia (CLL) over the last several decades in an interview during the 2016 OncLive State of the Science Summit on Hematologic Malignancies.

Dr. Mary Jo Fidler on the Role of Oligoclonal T Cell Expansion in NSCLC

October 26th 2016

Mary Jo Fidler, MD, associate professor, medical oncology, hematology, internal medicine, Rush University Medical Center, discusses how early and persistent oligoclonal T cell expansion correlates with durable response to anti-PD1 therapy in non-small cell lung cancer treatment (NSCLC).

Dr. Hoftstatter on Impact of Molecular Testing on Genetic Abnormalities in Breast Cancer

October 26th 2016

Erin Wysong Hofstatter, MD, associate professor, co-director, Cancer Genetics and Prevention Program, Yale Cancer Center, discusses what impact the advancements with molecular testing have had on the identification of genetic abnormalities in patients with breast cancer.

Dr. Braghiroli on the Current and Future Treatment Landscape in CRC

October 26th 2016

Maria Ignez Braghiroli, MD, medical oncologist, Instituto do Câncer do Estado de São Paulo, discusses what the current treatment landscape looks like for patients with colorectal cancer, as well as what the future may hold.

Dr. Gerritsen on Shortcomings of Immunotherapy in Prostate Cancer

October 26th 2016

Winald Gerritsen, MD, PhD, professor and medical oncologist, Radboud Medical Center, discusses some of the recent shortcomings seen with immunotherapy agents in the treatment of patients with castration-resistant prostate cancer.

Dr. Marcus Bosenberg on Mouse and Other Models for Immunotherapy

October 26th 2016

Marcus Bosenberg, MD, PhD, associate professor of dermatology and pathology, Yale University, discusses mouse models for testing immunotherapies.

Dr. Mesa on NCCN Guidelines for MPNs

October 26th 2016

Ruben A. Mesa, MD, chair, Division of Hematology and Medical Oncology, deputy director, professor of Medicine, Mayo Clinic, discusses the NCCN guidelines for treatment of patients with myeloproliferative neoplasms (MPNs).

Dr. Wakelee on FDA Approval of Frontline Pembrolizumab in NSCLC

October 25th 2016

Heather A. Wakelee, MD, associate professor of Medicine (Oncology), Stanford University Medical Center, regent, International Association for the Study of Lung Cancer (IASLC) discusses the FDA approval of pembrolizumab (Keytruda) in the frontline setting for patients with non–small cell lung cancer (NSCLC).

Dr. George Somlo on Treatment Considerations for Multiple Myeloma

October 25th 2016

George Somlo, MD, medical oncologist, City of Hope, discusses treatment considerations in multiple myeloma.

Dr. Hossein Borghaei on Selecting Checkpoint Inhibitors in NSCLC

October 25th 2016

Hossein Borghaei, DO, associate professor at Fox Chase Cancer Center, discusses selecting between nivolumab (Opdivo) and pembrolizumab (Keytruda) in second-line non–small cell lung cancer (NSCLC).

Dr. Jeffery S. Weber on Sequencing of Nivolumab, Ipilimumab in Metastatic Melanoma

October 25th 2016

Jeffery S. Weber, MD, PhD, deputy director of the Laura and Isaac Perlmutter Cancer Center, co-director of the Melanoma Program, and head of Experimental Therapeutics at NYU Langone Medical Center, discuses the key takeaways from the phase II CheckMate-064 trial, in which patients were randomized to receive either nivolumab followed by ipilimumab followed by nivolumab maintenance therapy, or ipilimumab followed by nivolumab and maintenance therapy with nivolumab.

Dr. Garon on Concerns for Immunotherapy Combinations in Lung Cancer

October 24th 2016

Edward B. Garon, MD, director, Thoracic Oncology, Jonsson Comprehensive Cancer Center, UCLA, discusses his concerns for potential immunotherapy combinations for the treatment of patients with lung cancer.

Dr. Heinemann on the Use of Depth of Response and RECIST in CRC

October 24th 2016

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, compares the use of depth of response and RECIST criteria to measure responses in patients with colorectal cancer.

Dr. David Nanus on Atezolizumab for Urothelial Bladder Cancer

October 22nd 2016

David Nanus, MD, medical oncologist, Weill Cornell Medicine, discusses the impact of atezolizumab for patients with advanced urothelial bladder cancer.